Iovance Biotherapeutics
Quarterly Financials
| Values in thousands | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|
Revenue | $73,694 | $58,554 | $31,106 | $715 |
Gross Profit | 28,151 | 18,731 | -5,640 | -11,820 |
EBITDA | -74,889 | -89,066 | -91,050 | -107,815 |
EBIT | -86,576 | -101,914 | -117,722 | |
Net Income | -78,559 | -83,541 | -97,101 | -112,976 |
Net Change In Cash | 73,694 | 58,554 | 31,106 | 715 |
Free Cash Flow | -77,464 | -61,261 | -98,871 | -126,450 |
Cash | 115,694 | 164,186 | 228,752 | 134,187 |
Basic Shares | 289,877 | 303,269 | 284,817 | 266,220 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $164,070 | $1,189 | $238 | $0 |
Gross Profit | 40,075 | -9,566 | -21,135 | -13,980 |
EBITDA | -395,278 | -427,432 | -377,743 | -328,723 |
EBIT | -460,559 | -398,878 | -342,703 | |
Net Income | -372,177 | -444,037 | -389,923 | -327,821 |
Net Change In Cash | 164,070 | 1,189 | 238 | 0 |
Cost of Revenue | 11,459 | |||
Free Cash Flow | -364,046 | -384,110 | -313,182 | -265,515 |
Cash | 115,694 | 114,888 | 231,731 | 78,229 |
Basic Shares | 289,877 | 235,131 | 159,259 | 153,406 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-12-31 | -$0.26 |
2024-09-30 | -$0.28 |
2024-06-30 | -$0.34 |
2024-03-31 | -$0.42 |
